Pfizer Inc. (NYSE:PFE) Position Reduced by Beck Bode LLC
Beck Bode LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,290 shares of the biopharmaceutical company’s stock after selling 3,586 shares during the period. Beck Bode LLC’s holdings in Pfizer were worth $837,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. 1 North Wealth Services LLC bought a new stake in Pfizer in the third quarter worth approximately $29,000. Bourgeon Capital Management LLC purchased a new position in Pfizer during the 3rd quarter valued at about $32,000. Salomon & Ludwin LLC boosted its stake in Pfizer by 362.7% during the third quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 700 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management bought a new stake in Pfizer during the third quarter worth about $36,000. Finally, Sageworth Trust Co bought a new stake in Pfizer during the third quarter worth about $44,000. 70.25% of the stock is owned by institutional investors.
A number of equities analysts have weighed in on the stock. Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 target price on shares of Pfizer in a research note on Wednesday, November 6th. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target on the stock in a report on Wednesday, August 28th. Morgan Stanley reduced their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 27th. UBS Group reiterated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Tuesday, October 1st. Nine research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $43.19.
Pfizer stock traded down $0.22 during midday trading on Tuesday, hitting $38.07. 7,644,210 shares of the company’s stock were exchanged, compared to its average volume of 20,264,374. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.68 and a current ratio of 0.90. The company has a market cap of $213.17 billion, a PE ratio of 12.69, a P/E/G ratio of 3.41 and a beta of 0.66. The firm has a 50-day moving average of $37.44 and a two-hundred day moving average of $38.96. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The company’s revenue was down 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.97 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 8th were paid a dividend of $0.36 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.78%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: Profit Margin
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.